市場調查報告書
商品編碼
1298658
病毒載體製造市場:2023-2028年全球行業趨勢、佔有率、規模、成長、機會和預測Viral Vector Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
全球病毒載體製造市場規模在2022年達到9.61億美元。展望未來,IMARC Group預計,到2028年,市場價值將達到39.75億美元,在2023-2028年期間,成長率(CAGR)為24.9%。
病毒載體是分子生物學家用來將遺傳物質送入細胞的一種工具。它被用來替換有缺陷的基因以治愈遺傳性疾病,表達和呈現病原體抗原,通過模仿自然感染產生免疫反應。它被廣泛地應用於溶瘤療法,以瞄準和殺死腫瘤細胞。除此之外,由於它有助於治療不同的疾病,如心臟缺陷、代謝性疾病和神經退行性疾病,它在生命科學研究、基因治療和疫苗學方面有廣泛的應用。目前,由於基因突變和體內染色體受損的結合,遺傳性疾病的發病率不斷上升,病毒載體製造也隨之上升。
由於個人飲酒和久坐的生活方式的上升,癌症患者的增加代表了促進市場成長的關鍵因素之一。此外,全球範圍內對病毒載體進行的臨床研究數量也在增加。這一點,加上病毒載體在新型藥物遞送中的應用越來越多,正在對市場產生積極影響。除此之外,它們是病毒失能序列的有效載體,並被用來向人類造血幹細胞(HSCs)傳遞抑制艾滋病毒的轉基因。此外,一些國家的政府正在開展活動,以提高個人對病毒載體疫苗的認知。他們也在通過變革改善監管環境,如快速審批程序。此外,主要的市場參與者正在廣泛地投資於世界各地的生產活動的產能擴張。這些參與者還沉迷於合併和收購(M&A),這預計會增加他們的整體銷售和盈利能力。
The global viral vector manufacturing market size reached US$ 961 Million in 2022. Looking forward, IMARC Group expects the market to reach a value of US$ 3,975 Million by 2028, exhibiting a growth rate (CAGR) of 24.9% during 2023-2028.
A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.
The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.
IMARC Group provides an analysis of the key trends in each sub-segment of the global viral vector manufacturing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, disease, application and end user.
Adenoviral Vectors
Adeno-associated Viral Vectors
Lentiviral Vectors
Retroviral Vectors
Others
Cancer
Genetic Disorders
Infectious Diseases
Others
Gene Therapy
Vaccinology
Pharmaceutical and Biopharmaceutical Companies
Research Institutes
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.
Key Questions Answered in This Report
1. What was the size of the global viral vector manufacturing market in 2022?
2. What is the expected growth rate of the global viral vector manufacturing market during 2023-2028?
3. What has been the impact of COVID-19 on the global viral vector manufacturing market?
4. What are the key factors driving the global viral vector manufacturing market?
5. What is the breakup of the global viral vector manufacturing market based on the type?
6. What is the breakup of the global viral vector manufacturing market based on the disease?
7. What is the breakup of the global viral vector manufacturing market based on the application?
8. What are the key regions in the global viral vector manufacturing market?
9. Who are the key players/companies in the global viral vector manufacturing market?